John Carroll

“I enjoy building companies,” notes Jörn Aldag in the lead to his profile note on LinkedIn. And now he’s getting a shot at a new challenge.

Mersana Therapeutics has teed up its first clinical program for the lead antibody drug conjugate in its pipeline, gaining $33 million in a new round to fund the work.

Four months after restructuring the ailing Aegerion ($AEGR) and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-lead investor Novo A/S.

Three years after it was forced to restructure the company in the wake of the failure of its then lead drug, Infinity Pharmaceuticals ($INFI) finds itself in a new crisis.

Gilde Healthcare has put together its fourth healthcare fund, looking to back a range of biotechs, device companies and digital health with a fresh injection of $285 million.

The biotech says that the agency has decided to slam the door shut on a marketing approval for Apadaz--at least for now.

Pazdur has some business advice he’d like to give drug developers: Stay focused on the cutting edge, and lose the me-too drugs in the cancer pipeline.

Faced with back-to-back pivotal flops for its lead drug, Eleven Biotherapeutics has now outlicensed the second drug in its limited pipeline to Roche.

The former Dendreon CEO and current venture capitalist has pieced together a $48 million A round for Alpine Immune Sciences in Seattle.